Classifications: cholinergic agonist; cholinergic enhancer; Therapeutic: cholinergic enhancer
Pregnancy Category: C
30 mg capsules
Cholinergic agent that binds to muscarinic receptors.
Increases secretion of exocrine glands, such as salivary and sweat glands. It relieves severe dry mouth.
Treatment of dry mouth in patients with Sjögren's syndrome.
Hypersensitivity to cevimeline; uncontrolled asthma; acute iritis; narrow-angle glaucoma; lactation.
Controlled asthma; chronic bronchitis, COPD; cardiac disease, cardiac arrhythmias, myocardial infarction; history of nephrolithiasis
or cholelithiasis; elderly; pregnancy (category C); older adults. Safety and effectiveness in children are not established.
Route & Dosage
Adult: PO 30 mg t.i.d.
- Give without regard to food.
- Store refrigerated at 2°8° C (35.6°46.4° F) with occasional fluctuations between 15°30°
C (59°86° F).
Adverse Effects (≥1%) Body as a Whole: Excessive sweating, headache,
back pain, dizziness, fatigue
, pain, hot flushes, rigors, tremor, hypertonia, myalgia, fever, eye pain, ear ache, flu-like
. CNS: Insomnia
, anxiety, vertigo, depression
, hyporeflexia. CV:
Peripheral edema, chest pain. GI: Nausea, diarrhea,
excessive salivation, dyspepsia, abdominal pain, coughing, vomiting, constipation
, anorexia, dry mouth, hiccup. Respiratory: Rhinitis, sinusitis, upper respiratory tract infection,
, pruritus. Special Senses:
Abnormal vision. Urogenital:
Urinary tract infection
InteractionsDrug: beta-adrenergic agonists
may cause conduction disturbances; parasympathomimetic drugs
may have additive effects.
Rapidly absorbed. Peak:
1.52 h. Distribution:
<20% protein bound. Metabolism:
In liver by CYP2D6 and 3A3/4. Elimination:
Primarily in urine. Half-Life:
Assessment & Drug Effects
- Monitor for S&S of increased airway resistance, especially in patient with asthma, bronchitis, emphysema, or COPD.
- Monitor cardiac status, especially in those with known cardiac disease or dysfunction.
- Monitor fluid status, especially in those at risk for dehydration.
- Lab tests: Routine blood chemistry during long-term therapy.
- Report S&S of excess cholinergic activity (e.g., diaphoresis, frequent urge to urinate, nausea and/or diarrhea).
Patient & Family Education
- Do not drive or engage in potentially hazardous activities until response to drug is known.
- Consult physician if confusion, dizziness, or faintness occur.
- Report diminished night vision or depth perception.
- Drink fluids liberally (20003000 mL/d) in the event of excessive sweating when it occurs.